Your skepticism about teva complicating its ANDA is a good point. I guess we will have to wait and see for the moment. Here are the benefits touted by Antares for Vibex-
Benefits of Vibex™ Disposable Mini-Needle Injectors Rapid injection Eliminates sharps disposal Ease of use in emergencies Reduces psychological barriers since the patient never sees the needle Highly dependable subcutaneous injection Designed around conventional cartridges or pre-filled syringes
If I heard correctly on teh AIS call, the company said ANDAs had been filed for both Teva Vibex products, so that would seem to rule out copaxone...seems too early to launch a differentiated copaxone branded generic to compete with possible future generic from mnta/sandoz
Market Data 
Markets 
AI
